Category: Zynex Inc.Syndicate content

Zynex wins Russian approval for NexWave and NeuroMove devices

February 19, 2014 by Chris Walker

Zynex lands approval to market its NexWave and NeuroMove devices in Russia, adding to the range of approvals both devices now have worldwide.

Zynex wins Russian approval for NexWave and NeuroMove devices

Zynex (OTC:ZYXI) obtained marketing clearance in Russia for both its NeuroMove and NexWave devices.

Zynex CEO clears out board | Personnel Moves

January 20, 2014 by Chris Walker

Zynex CEO Thomas Sandgaard downsizes the company's board of directors as part of a larger strategy to restructure the company.

fired/hired

Zynex (OTC:ZYXI) CEO Thomas Sandgaard has cleared the path to reshape the company after cutting its board in half.

Sandgaard asked for the resignations of board members Mats Wahlstrom, Mary Beth Vitale, Kevin Smith and Taylor Simonton, to add board members who share Sandgaard's vision for the rehab devices maker.

Rehab devices maker Zynex signs distribution deal in China

January 8, 2014 by Chris Walker

Zynex inks a 5-year Chinese distribution deal with DIH Medical Technologies for its NeuroMove stroke rehab system.

Rehab devices maker Zynex signs distribution deal in China

Zynex (OTC:ZYXI) signed a distribution deal with DIH Medical Technologies, giving DIH exclusive 5-year rights to distribute the NeuroMove stroke rehabilitation device in China.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA grants Zynex 510(k) clearance for female incontinence device

August 31, 2012 by MassDevice staff

Zynex touts FDA clearance for its InWave electrotherapy device for treating female urinary incontinence.

Zynex logo

Colorado-based device maker Zynex (OTC:ZYXI) won FDA clearance for its InWave device, an electrotherapy system for treating female urinary incontinence.

The company's hoping that the InWave device will complement its existing electrotherapy portfolio and spur a boost in revenue, CEO Thomas Sandgaard said in a press release.

Accuray slides on lowered sales outlook | Earnings Roundup

May 9, 2012 by MassDevice staff

Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year; plus, Q1 sales, earnings up for Henry Schein; LeMaitre Vascular's Q1 profits soar; Mindray's Q1 profits slide despite double-digit sales boost; Stereotaxis boosts Q1 sales, slashes losses; Steris profits spike in 2011; Symmetry Medical's Q1 bottom line plunges; Syneron boosts Q1 sales, losses widen; and more.

MassDevice.com news

Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.

The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Sorin's 2011 sales stay flat, profits soar | Earnings Roundup

March 15, 2012 by MassDevice staff

Italian medical device maker Sorin Group posts flat sales for 2011, but boosts profits by more than 48%; also, Dräger Medical's 2011 sales dip 2%; Sanuwave's 2011 sales rise, losses narrow; Aastrom's 2011 sales soar, losses mount; Sales tick up, profits soar for American Shared Hospital Services; Atrion's 2011 sales, profits rise; Sales rise, losses narrow for BioMimetic Therapeutics; InVivo Therapeutics' losses rise 340%; Sales, earnings up for Synergetics during Q2; Utah Medical's sales rise more than 50% in 2011; and Zynex logs 2011 profit growth of 347%.

Sorin Group

Sorin Group (BIT:SRN) reported flat sales but strong profit growth for 2011, saying it raised earnings by 48.3% and revealing that the cardiac rhythm management slump has made its way across the pond.

The Italian medical device maker posted net income of €58.0 million (~$75.2 million) on sales of €743.4 million (~$963.4 million) for the year ended Dec. 31, 2011. That compares with profits of €39.1 million (~$50.7 million) on sales of €745.8 million (~$966.5 million) during 2010.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Standard & Poor's gives Medtronic an A+ | Wall Street Beat

March 15, 2012 by MassDevice staff

Standard & Poor's gives Medtronic's long-term debt an "A+" rating; also, ICU Medical to re-state financials; Zynex details NeuroDyne buyout terms; GI Dynamics dips on huge volume; Report: JPMorgan testing the waters for Kai Medical IPO; Delcath inks French training deal for Chemosat device; Misonix signs Asian distribution deal; Premier inks urological device deals; plus, a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

Standard & Poor's Ratings Services affirmed Medtronic's (NYSE:MDT) long-term debt's "A+" rating yesterday, after the med-tech titan announced another debt offering.

The rating agency said its view of Medtronic's senior unsecured notes and its stable rating outlook "reflect the company's 'strong' business risk profile and 'modest' financial risk profile."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp